Zalicus Prednisporin Licensee Sanofi Provides Update on Development Status

Zalicus ZLCS today announced that Sanofi provided an update on the development status of Prednisporin™ (FOV1101) during the course of Sanofi's quarterly financial and R&D pipeline update on October 25, 2012. Prednisporin is a fixed dose combination of prednisolone acetate and cyclosporine A being developed for certain ophthalmologic indications including persistent allergic conjunctivitis. Prednisporin was licensed by Zalicus to Fovea Pharmaceuticals SA (now a division of Sanofi) in January 2006. Based on a recent review of prior Phase 2b results for Prednisporin, Sanofi has reassessed the commercial profile for Prednisporin and has made See full press release